Marksans Pharma Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3572ew5zwnjy1xhqoacm157a.pdf

Key Takeaways


US Business: Order Book & Run Rate

Mark Saldanha: "So, Akash, my vision is big, but it's not - I don't want to sound crazy in terms of giving a number right now because here we have quarterly calls."

Margin Dynamics: The Temporary Spike

Mark Saldanha: "I don't expect these numbers, the gross margin to sustain. This is just a transition of what you will see out there. But definitely, we should be around 53% to 55% gross margin level."

UK & Europe: The Next Growth Leg

Mark Saldanha: "Believe me, we have tried. It's not as easy. You don't every day come across a Teva. So obviously some of the facilities available, the valuations are crazy."

Australia/New Zealand: Slow-Build OTC Opportunity


Product & Rx Pipeline


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue milestoneAchieve INR 3,000 crores; should be very close next yearWithin 2 years
Gross margin normalizationNormalize to 53% to 55% rangeUnspecified; implied near-term as transition effect rolls off
US quarterly run rateAccelerate from ~$40 million to ~$50 millionBy next year
Teva facility revenueTrend at INR 800 crores oddBy next year
Teva capacity capCapacity expected to cap out at INR 800 crores plus; working on next steps for capacity enhancement, greenfield, or M&AUnspecified
EBITDA marginStable in the range of 22% odd; no foreseeable cutsOngoing
Inventory normalizationInventory to stay elevated until optimum order trend toward planned order book is hitTill March
Product launch cadenceNew launches every month or every two monthsNow through March 2025

Key Metrics

MetricQ2 FY25
Operating revenue₹641.9 cr, +20.8% YoY vs ₹531.2 cr
US & North America revenue₹304.2 cr, +36.8% YoY
Australia & New Zealand revenue₹63.6 cr, +31.3% YoY
Rest of World revenue₹27.5 cr
Gross margin59.7%, expanded 732 bps YoY from 52.4%
EBITDA₹135.7 cr (all-time high), +19.1% YoY
EBITDA margin21.1%, impacted by new employees at Teva facility and higher freight costs
Profit after tax₹97.8 cr, +16.6% YoY vs ₹83.9 cr
EPS₹2.1
R&D expense₹10.7 cr, 1.7% of consolidated revenue
Cash balance₹657 cr as of 30th September 2024, debt-free
Teva facility revenue contribution~₹100 cr in Q2, current annual run rate ~₹440 cr
Teva facility capacity utilization~40%
US order book$200 million
US quarterly revenue run rate~$40 million
Freight cost~₹60 cr in Q2, up from ~₹40 cr in Q1
FY26 EBITDA guidance~22%
Revenue milestone target₹3,000 cr within the next two years